Autonomic Nervous System Drugs Practice Questions

Q: Which drug produces neuromuscular blockade by persistent depolarization?

Decamethonium. Neuromuscular blocking agents (NMBAs) are classified into two categories based on their mechanism of action at the nicotinic acetylcholine receptors (Nm) of the motor endplate: **Depolarizing** and **Non-depolarizing**. **Why Decamethonium is Correct:** **Decamethonium** (along with Succinylcholine) is a **Depolarizing Neuromuscular Blocker** [3]. These drugs act as nicotinic agonists; they bind to Nm receptors and cause persistent stimulation, leading to initial fasciculations followed by flaccid paralysis [1], [2]. Because they are not metabolized by acetylcholinesterase, the endplate remains depolarized and unresponsive to subsequent impulses (Phase I block) [1]. **Why the other options are Incorrect:** * **A, B, and C (D-tubocurarine, Gallamine, Pancuronium):** These are all **Non-depolarizing (Competitive) Blockers** [3]. They act as competitive antagonists at the Nm receptor. They prevent acetylcholine from binding but do not cause depolarization themselves [3]. **High-Yield NEET-PG Pearls:** * **Succinylcholine (Suxamethonium):** The only depolarizing blocker currently used in clinical practice (Decamethonium is largely of historical/experimental interest) [2]. * **Dual Block (Phase II Block):** With prolonged exposure or high doses, depolarizing blockers can lead to a state where the membrane repolarizes but remains insensitive to ACh, resembling a non-depolarizing block [4]. * **Metabolism:** Succinylcholine is rapidly hydrolyzed by **Pseudocholinesterase** (Butyrylcholinesterase). Patients with atypical pseudocholinesterase experience prolonged apnea. * **Key Side Effects of Depolarizing Blockers:** Hyperkalemia (critical in burn/trauma patients), muscle soreness, and triggering of Malignant Hyperthermia.

Q: An elderly patient on beta-blocker therapy is prone to develop which of the following complications?

All of the above. Beta-blockers act by antagonizing $eta_1$ and $eta_2$ adrenergic receptors, leading to physiological changes that can precipitate specific complications, especially in the elderly [1], [2]. 1. **Bradycardia:** This is a direct consequence of $eta_1$ blockade at the SA and AV nodes. It reduces the heart rate (negative chronotropic effect) and slows conduction. In elderly patients with pre-existing conduction system disease, this can lead to symptomatic bradycardia or heart block [2], [3]. 2. **Congestive Heart Failure (CHF):** Beta-blockers exert a negative inotropic effect (reduced contractility). In patients with compensated heart failure or borderline cardiac reserve, the sudden withdrawal of sympathetic drive can lead to acute decompensation and pulmonary edema [1], [2]. 3. **Asthma:** Non-selective beta-blockers (like Propranolol) block $eta_2$ receptors in the bronchial smooth muscle, leading to bronchoconstriction. This can trigger life-threatening bronchospasm in patients with asthma or COPD [1], [3]. **Why "All of the above" is correct:** Since beta-blockers affect the heart (nodes and myocardium) and the lungs simultaneously, all three conditions are recognized adverse effects and contraindications in susceptible individuals [1], [2], [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Cardioselectivity:** $eta_1$-selective blockers (e.g., **M**etoprolol, **A**tenolol, **B**isoprolol, **E**smolol—mnemonic: **MABE**) are safer in asthmatics but should still be used with caution [1]. * **Diabetes:** Beta-blockers can mask the tachycardia associated with hypoglycemia, making it dangerous for diabetic patients [2]. * **Peripheral Vascular Disease:** They can worsen Raynaud's phenomenon due to unopposed $\alpha$-mediated vasoconstriction [1]. * **Lipid Profile:** They may increase triglycerides and decrease HDL levels (except those with ISA like Pindolol).

Q: Which of the following is a short-acting non-depolarizing muscle relaxant?

Mivacurium. **Explanation:** Neuromuscular blocking agents (NMBAs) are classified based on their mechanism of action (Depolarizing vs. Non-depolarizing) and their **duration of action**. **1. Why Mivacurium is correct:** Mivacurium is a benzylisoquinoline derivative and is the only **short-acting** non-depolarizing muscle relaxant (duration: 12–18 minutes). Like Succinylcholine, it is metabolized by **plasma pseudocholinesterase**, which accounts for its rapid offset. **2. Why the other options are incorrect:** * **Vecuronium:** This is an aminosteroid NMBA with an **intermediate duration** of action (30–40 minutes). It is primarily excreted via the bile and kidneys. * **Atracurium:** This is a benzylisoquinoline NMBA with an **intermediate duration** of action (30–45 minutes). It is unique because it undergoes **Hofmann elimination** (spontaneous degradation at body pH and temperature), making it safe in liver and kidney failure. * **Succinylcholine:** While it is short-acting (5–10 minutes), it is a **depolarizing** muscle relaxant. The question specifically asks for a *non-depolarizing* agent. **High-Yield Clinical Pearls for NEET-PG:** * **Shortest acting NMBA:** Succinylcholine (Depolarizing); Mivacurium (Non-depolarizing). * **Longest acting NMBA:** Gallamine or Pancuronium. * **Hofmann Elimination:** Seen with Atracurium and Cisatracurium (Drug of choice in renal/hepatic failure). * **Adverse Effect of Mivacurium:** It can cause significant **histamine release**, leading to hypotension and flushing if injected rapidly. * **Pseudocholinesterase Deficiency:** Patients with this genetic condition will experience prolonged apnea after receiving Mivacurium or Succinylcholine.

Q: Tolterodine, used in overactive bladder, acts by blocking which of the following receptors?

M3. **Explanation:** **Mechanism of Action:** Tolterodine is a competitive **muscarinic receptor antagonist** specifically used for the treatment of overactive bladder (OAB). The detrusor muscle of the urinary bladder is primarily under the control of the parasympathetic nervous system. While both M2 and M3 receptors are present in the bladder, the **M3 receptor** is the subtype responsible for **bladder contraction**. By blocking M3 receptors, Tolterodine reduces detrusor pressure and decreases the frequency of involuntary bladder contractions, thereby alleviating symptoms of urgency and incontinence. **Analysis of Options:** * **M1 (Option A):** These are primarily located in the CNS and gastric glands. Blocking M1 is associated with cognitive impairment (e.g., Pirenzepine is an M1 blocker used for peptic ulcers). * **M2 (Option B):** These are predominantly found in the heart (SA and AV nodes). Blocking M2 leads to tachycardia. While M2 receptors exist in the bladder, they do not directly mediate contraction as significantly as M3. * **M4 (Option D):** These are mainly located in the CNS and are involved in modulating dopamine release; they have no clinical role in bladder dynamics. **High-Yield Clinical Pearls for NEET-PG:** * **Selectivity:** Unlike older drugs like Oxybutynin, Tolterodine is more "uroselective" in its functional effect, leading to a lower incidence of **xerostomia (dry mouth)**. * **Other M3 Blockers for OAB:** Darifenacin and Solifenacin are even more highly selective for the M3 subtype. * **Contraindication:** Like all anticholinergics, Tolterodine is contraindicated in patients with **Narrow-Angle Glaucoma** and **Prostatic Hyperplasia** (due to risk of acute urinary retention). * **Mirabegron:** A newer alternative for OAB that acts as a **β3-agonist**, avoiding anticholinergic side effects.

Q: Which muscarinic receptor causes vasodilation?

M3. **Explanation:** The correct answer is **M3**. **Mechanism of Vasodilation:** Muscarinic receptors are not typically found on the smooth muscle of blood vessels in a way that receives direct parasympathetic innervation. However, **M3 receptors** are present on the **vascular endothelium**. When these receptors are stimulated by a muscarinic agonist (like Acetylcholine), they activate the Gq-phospholipase C pathway, leading to an increase in intracellular calcium. This triggers the enzyme **Nitric Oxide Synthase (NOS)** to produce **Nitric Oxide (NO)**, also known as Endothelium-Derived Relaxing Factor (EDRF). NO diffuses into the adjacent vascular smooth muscle, increases cGMP, and causes relaxation (vasodilation). *Note: If the endothelium is damaged, M3 stimulation directly on smooth muscle causes vasoconstriction.* **Why other options are incorrect:** * **M1:** These are primarily "Neural" receptors located in the CNS and gastric parietal cells (increasing HCl secretion). They are not involved in systemic vasodilation. * **M2:** These are "Cardiac" receptors located in the SA and AV nodes. Their stimulation leads to a decrease in heart rate (negative chronotropy) and conduction velocity via Gi protein (decreasing cAMP). * **M4:** These are primarily located in the CNS and act via Gi proteins to inhibit adenylate cyclase; they do not play a role in peripheral vascular tone. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Receptors:** M1, M3, M5 are **Gq** coupled (Stimulatory); M2, M4 are **Gi** coupled (Inhibitory). * **The "Rule of 1, 2, 3":** M1 = Brain/Glands; M2 = Heart; M3 = Smooth Muscle/Exocrine Glands/Endothelium. * **Atropine** is a competitive antagonist for all these receptors; it can block the vasodilatory effect of injected choline esters.

Q: Atropine is contraindicated in which of the following conditions?

Narrow angle glaucoma. **Explanation:** **Why Narrow-Angle Glaucoma (NAG) is the correct answer:** Atropine is a potent **parasympatholytic (mydriatic)** agent. In patients with narrow anterior chamber angles, pupillary dilation causes the peripheral iris to bunch up and thicken at the iris base. This physically blocks the trabecular meshwork (the drainage site), leading to a sudden rise in intraocular pressure (IOP) and precipitating an **Acute Angle Closure Glaucoma** crisis. Therefore, it is strictly contraindicated. **Analysis of Incorrect Options:** * **Open-Angle Glaucoma (OAG):** The pathology lies within the microscopic resistance of the trabecular meshwork, not the physical position of the iris. While atropine can slightly increase IOP in OAG by reducing aqueous outflow, it does not cause an acute crisis like in NAG. * **Congenital Glaucoma:** This is caused by developmental anomalies of the angle (e.g., Barkan’s membrane). Atropine is not the treatment, but it is not a primary contraindication in the same way it is for NAG. * **Steroid-Induced Glaucoma:** This is a form of secondary OAG caused by increased resistance to aqueous outflow due to structural changes in the trabecular meshwork. It is managed by stopping steroids, not by avoiding mydriatics. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for NAG:** IV Mannitol and Acetazolamide (to lower IOP) followed by **Pilocarpine** (miotic) once IOP is stabilized. * **Definitive Treatment for NAG:** Peripheral Iridotomy (usually via YAG laser). * **Mydriatic of Choice for Fundus Examination:** Tropicamide (shorter duration of action) is preferred over Atropine, but even it must be used with caution if the angle is narrow. * **Safe Mydriatic:** Phenylephrine (sympathomimetic) is often safer as it is easier to reverse, but the risk of angle closure still exists.

Q: Which one of the following is FALSE regarding atropine?

Long acting miotic. ### Explanation **Why Option D is the Correct Answer (The False Statement):** Atropine is a potent **competitive antagonist at muscarinic receptors**. In the eye, it blocks the $M_3$ receptors on the circular muscles (sphincter pupillae) of the iris. This leads to relaxation of the sphincter muscle, resulting in **Mydriasis** (dilation of the pupil), not miosis. Therefore, Atropine is a **long-acting Mydriatic** (and cycloplegic), with effects lasting up to 7–10 days. **Analysis of Incorrect Options (True Statements):** * **Option A:** In inflammatory conditions like iridocyclitis, atropine is used to prevent **synechiae** (adhesions between the iris and lens). By keeping the pupil dilated and the ciliary muscle paralyzed, it reduces pain and prevents the iris from sticking to the lens. * **Option B:** The standard clinical concentration of Atropine sulfate used in ophthalmic practice for adults is **1%** (drops or ointment). * **Option C:** Atropine is the **drug of choice for symptomatic sinus bradycardia**. It blocks the vagal (parasympathetic) input to the SA node, thereby increasing the heart rate. **High-Yield Clinical Pearls for NEET-PG:** 1. **Cycloplegia:** Atropine causes paralysis of the ciliary muscle, leading to loss of accommodation. It is the most potent cycloplegic available. 2. **Contraindication:** Atropine is strictly contraindicated in patients with **Angle-Closure Glaucoma**, as mydriasis can further obstruct the aqueous outflow. 3. **Antidote:** Physostigmine (a tertiary amine) is the preferred antidote for atropine poisoning because it can cross the blood-brain barrier. 4. **Duration:** Atropine has the longest duration of action among mydriatics; for shorter procedures, Tropicamide (6 hours) or Cyclopentolate (24 hours) are preferred.

Q: Which beta-blocker(s) should be avoided in glaucoma?

All the above. **Explanation:** The primary goal of beta-blocker therapy in glaucoma is to reduce intraocular pressure (IOP) by decreasing aqueous humor production from the ciliary body. To achieve this, a drug must have potent **Beta-2 antagonist** activity and **lack Intrinsic Sympathomimetic Activity (ISA)**. **Why "All the Above" is Correct:** The drugs listed (Pindolol, Carvedilol, and Labetalol) are avoided in glaucoma management for the following reasons: 1. **Pindolol:** It possesses significant **Intrinsic Sympathomimetic Activity (ISA)**. While it blocks the receptor, it also partially stimulates it. This partial agonism prevents a significant reduction in aqueous secretion, making it ineffective at lowering IOP compared to "pure" antagonists like Timolol. 2. **Carvedilol & Labetalol:** These are **combined Alpha and Beta blockers**. While they block beta receptors, they also cause systemic vasodilation via alpha-1 blockade. When administered topically, they often cause significant **local irritation and conjunctival hyperemia** (redness). Furthermore, their efficacy in lowering IOP does not surpass that of selective or non-selective beta-blockers, and their side effect profile makes them clinically unsuitable for ophthalmic use. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard:** **Timolol** (Non-selective beta-blocker without ISA) is the most commonly used. * **Cardioselective Option:** **Betaxolol** (Beta-1 selective) is the drug of choice for glaucoma patients with co-existing respiratory issues (e.g., Asthma/COPD), as it has a lower risk of causing bronchospasm. * **Contraindications:** Avoid topical beta-blockers in patients with **Bradycardia, Heart Block, or Overt Cardiac Failure**. * **Side Effect:** Be aware of "masked hypoglycemia" in diabetic patients using systemic or potent topical beta-blockers.

Question 1

Which drug produces neuromuscular blockade by persistent depolarization?

Accepted Answer

Decamethonium

Answer

D-tubocurarine

Answer

Gallamine

Answer

Pancuronium

Question 2

An elderly patient on beta-blocker therapy is prone to develop which of the following complications?

Accepted Answer

All of the above

Answer

Asthma

Answer

Congestive Heart Failure (CHF)

Answer

Bradycardia

Question 3

Which of the following is a short-acting non-depolarizing muscle relaxant?

Accepted Answer

Mivacurium

Answer

Vecuronium

Answer

Atracurium

Answer

Succinylcholine

Question 4

Tolterodine, used in overactive bladder, acts by blocking which of the following receptors?

Accepted Answer

M3

Answer

M1

Answer

M2

Answer

M4

Question 5

Epinephrine is used for all the following, except?

Accepted Answer

Management of acute heart failure

Answer

To prolong the action of local anaesthetics

Answer

As a topical haemostatic agent

Answer

Management of cardiac arrest

Question 6

First dose hypotension is commonly seen with which of the following medications?

Accepted Answer

Prazosin

Answer

Yohimbine

Answer

Atenolol

Answer

Methyldopa

Question 7

Which muscarinic receptor causes vasodilation?

Accepted Answer

M3

Answer

M1

Answer

M2

Answer

M4

Question 8

Atropine is contraindicated in which of the following conditions?

Accepted Answer

Narrow angle glaucoma

Answer

Open angle glaucoma

Answer

Congenital glaucoma

Answer

Steroid induced glaucoma

Question 9

Which one of the following is FALSE regarding atropine?

Accepted Answer

Long acting miotic

Answer

Used to prevent adhesions in inflammatory conditions of the eye

Answer

Used in a concentration of 1%

Answer

Can be given in sinus bradycardia patients

Question 10

Which beta-blocker(s) should be avoided in glaucoma?

Accepted Answer

All the above

Answer

Pindolol

Answer

Carvedilol

Answer

Labetalol

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?